mazdutide vs survodutide

mazdutide (A-tier) vs survodutide (A-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

mazdutide · tier A

the GLP-1 + glucagon dual agonist approved in China. ~14% weight loss in GLORY-1 phase 3 at 48 weeks, ~20% at the higher dose. not FDA-approved.

the glucagon/GLP-1 dual agonist that reached approval first, in China. real phase 3 efficacy, real label, but the pivotal data is single-ethnicity and there is no US approval.

NMPA '25 approved in China · half-life ~once-weekly dosing · weight loss

survodutide · tier A

Investigational GLP-1/glucagon dual agonist. In a phase 3 obesity trial, mean weight loss was 13.0% versus 5.4% with placebo at 76 weeks. Separate trials studied MASH and liver fibrosis.

a GLP-1 plus glucagon dual agonist with phase 3 obesity data and a breakthrough-tier liver story. still investigational, not FDA-approved.

13.0% mean weight loss at 76 weeks · half-life ~6 days · weight loss

at a glance

• mazdutide: tier A · NMPA '25 approved in China
• survodutide: tier A · 13.0% mean weight loss at 76 weeks

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.